- Report
- August 2025
- 183 Pages
Global
From €4012EUR$4,500USD£3,465GBP
- Report
- August 2025
- 180 Pages
Global
From €4012EUR$4,500USD£3,465GBP
- Report
- July 2025
- 180 Pages
Global
From €4012EUR$4,500USD£3,465GBP
- Report
- August 2025
- 180 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- May 2026
- 369 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 377 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 486 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 288 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 341 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 375 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 553 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 383 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 141 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 476 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 466 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 673 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 676 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 245 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 244 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 324 Pages
Global
From €5216EUR$5,850USD£4,505GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more